It is interesting to note that treating two TNBC breast cancer cell lines with a VDR agonist and an AR agonist decreased cell viability; when combined, they appeared to be additive, and viability was decreased further when the agonists were combined with chemotherapeutic drugs. The gene discussed is AR; the disease is breast carcinoma.